Nucleome Therapeutics is an Oxford-based immunology biotechnology company that uses 3D genomics and machine learning to study the non-coding part of the human genome, which holds the majority of disease-linked genetic variants. Its Micro Capture-C platform maps how these variants regulate gene expression across immune cell types, using primary human cells rather than animal models, to identify causal molecular drivers of disease and novel drug targets.

The company was founded in 2019 by researchers in gene regulation from the University of Oxford, including Danuta Jeziorska, James Davies and Jim Hughes, and it builds on research from the MRC Weatherall Institute of Molecular Medicine. Its initial focus is inflammatory and autoimmune diseases, and it has built a data atlas of dysregulated genes across several such conditions. In July 2024 Mark Bodmer, formerly of Evelo Biosciences, succeeded Danuta Jeziorska as chief executive.

In January 2026 Nucleome nominated NTP464, a first-in-class monoclonal antibody agonist designed to promote inflammation resolution, as its first preclinical development candidate, and the programme moved toward IND-enabling studies. A US patent covering the Micro Capture-C technology was granted in July 2026. The company has a collaboration with Johnson & Johnson on mapping genetic associations in autoimmune disease, announced in October 2024. Its investors include M Ventures, Johnson & Johnson Innovation-JJDC, Pfizer Ventures, British Patient Capital and Oxford Science Enterprises.